{"id":"NCT04334148","sponsor":"Adrian Hernandez","briefTitle":"Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","officialTitle":"Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-04-22","primaryCompletion":"2020-12-10","completion":"2021-01-09","firstPosted":"2020-04-06","resultsPosted":"2021-10-07","lastUpdate":"2021-10-12"},"enrollment":1360,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"Hydroxychloroquine","otherNames":["Plaquenil"]},{"type":"DRUG","name":"Placebo oral tablet","otherNames":[]}],"arms":[{"label":"Hydroxychloroquine","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19. Eligible participants will be randomly assigned (1:1) to either treatment group (HCQ) or placebo in a double-blind fashion. Course of treatment is 30 days.","primaryOutcome":{"measure":"Number of Participants With Clinical Infection With COVID-19 Infection","timeFrame":"30 days","effectByArm":[{"arm":"Hydroxychloroquine","deltaMin":41,"sd":null},{"arm":"Placebo","deltaMin":53,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.200"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":11},"locations":{"siteCount":34,"countries":["United States"]},"refs":{"pmids":["36682681"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":683},"commonTop":[]}}